Micah Adamson, MD
Orthopaedic Surgery · Los Angeles, CANPI 1013390533
Payments from drug & device makers
What this record shows
This record is dominated by education: $42,650 of the $54,711 with a category attached, or 78.0%. Smith+Nephew accounts for 77.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $21,829 and has fallen 86.5% since, to $2,938 in 2025.
Across 137 payments — averaging $399.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$42K
- Zimmer Biomet$7K
- Stryker$4K
- Johnson & Johnson$667
- Gemini Mountain Medical, LLC$170
- Next Science LLC$143
- plus $588 from 11 others
What the payments were for
- Travel & lodging$2,7865%
- Food & beverage$9,27417%
- Education$42,65078%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 6 | $42,150 |
| Zimmer Biomet | 63 | $7,352 |
| Stryker | 41 | $3,641 |
| Johnson & Johnson | 7 | $667 |
| Gemini Mountain Medical, LLC | 1 | $170 |
| Next Science LLC | 1 | $143 |
| Medical Device Business Services, Inc. | 3 | $120 |
| UOC USA Inc | 1 | $96 |
| Ferring Pharmaceuticals Inc. | 4 | $78 |
| Medacta USA, Inc. | 1 | $59 |
| Axogen | 1 | $58 |
| Medtronic | 1 | $40 |
| Bioventus LLC | 2 | $34 |
| Pacira Pharmaceuticals Incorporated | 2 | $34 |
| Integra Lifesciences Corporation | 1 | $27 |
| Avanos Medical | 1 | $22 |
| Heraeus Medical, LLC. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,711 in reported general payments places this provider in the 85th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 11 | $147 |
| Oxycodone Hcl | 13 | $133 |
| Methylprednisolone | 12 | $81 |
| Tramadol Hcl | 13 | $60 |
| Meloxicam | 16 | $45 |
| Amoxicillin | 19 | $35 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Los Angeles
- Kelly VinceLos Angeles$9.6M
- Jay LiebermanLos Angeles$4.8M
- Thomas SchmalzriedLos Angeles$4M
- David SkaggsLos Angeles$2.6M
- David ThordarsonLos Angeles$2.5M
- Edward McPhersonLos Angeles$1.2M
- Daniel AllisonLos Angeles$1.1M
- Justin SalimanLos Angeles$912K
- Charles MoonLos Angeles$760K
- Andrew SpitzerLos Angeles$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.